Clinical Trial to Evaluate the Safety and Efficacy of MeRT Treatment in Post-Traumatic Stress Disorder

Not Applicable

Active, not recruiting

• Conditions: PostTraumatic Stress Disorder; Postconcussive Symptoms; Traumatic Brain Injury

• Registration Number: NCT02990793
• Lead Sponsor: Wave Neuroscience

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of individualized, Biometrics-guided Magnetic e-Resonance Therapy (MeRT) treatment of Post-Traumatic Stress Disorder

Detailed Description

MERT-005-B is a prospective, double blind, randomized, sham-controlled, parallel group, stratified, adaptive clinical trial designed to evaluate the efficacy of EEG-guided MeRT in persons with Post-Traumatic Stress Disorder

A total of 152 participants will be randomized in the Test Phase, and a group-sequential approach to efficacy monitoring by the Data and Safety Monitoring Board (DSMB).

A Pilot Phase was completed in which 74 participants were randomized. The Pilot Phase data will be used for confirming the safety of MeRT. For the Test Phase, eligible participants will be randomly assigned to either MeRT or Sham MeRT treatment groups in a 1:1 allocation ratio, with stratification on recruitment site and two levels of PPCS co-morbidity (+/-).

Initial eligibility evaluation and data collection will occur at the Screening Visit (SC). Following the SC visit, there will be a 5-week treatment period in which active or sham investigative treatment will be administered during daily weekday visits to the study site. Participants who received sham treatment and who continue to be eligible will be offered up to 25 active MeRT study treatments as part of Open Label Enrollment.

Main study outcomes will be collected at the second follow-up visit (F2) at the conclusion of the 5-week treatment period. An abbreviated data collection visit will occur during the third treatment week (the F1 follow-up visit). Additional follow up visits will occur 90 days after the first day of study treatment.

Participants, clinicians, and all personnel who participate in evaluation will be blind to study treatment group assignment.

The first phase of this trial was conducted in partnership with the United States Special Operations Command (USSOCOM) and the Henry Jackson Foundation.

Study Timeline

• Study First Submitted: 2016-11-10
• Study First Submitted QC: 2016-12-08
• Study First Posted: 2016-12-13
• Study Start: 2022-04-04
• Status Verified: 2025-08
• Last Update Submitted: 2025-08-08
• Last Update Posted: 2025-08-14
• Primary Completion: 2025-09
• Study Completion: 2025-11-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 152

Inclusion Criteria

Participants must meet all inclusion criteria to qualify for enrollment in the study:

1. Willing and able to consent to participate in the study
2. Age 18 - 65 years
3. Diagnosis of PTSD according to DSM-V criteria via CAPS-5
4. Onset of symptoms meeting the DSM-5 criteria for PTSD symptoms persisting for a minimum of 6 months prior to the Screening Visit
5. Minimum PCL-5 score of 30

Exclusion Criteria

Participants will be excluded from study participation if one or more of the following exclusion criteria apply:

1. Index trauma occurred before the age of 16 years

2. History of open skull injury

3. History of a neurological disorder including, but not limited to:

   • Seizure disorder
   • Any condition likely to be associated with increased intracranial pressure
   • Space occupying brain lesion

4. History of cerebrovascular accident

5. History of cerebral aneurysm

6. EEG abnormalities that indicate risk of seizure, i.e., abnormal focal or general slowing, or ictal spikes, during the EEG recording

7. Inability to calculate the EEG intrinsic alpha frequency at Screening

8. Participation in any interventional research protocol within 3 months prior to the Screening Visit

9. History of any type of ECT, rTMS, or MeRT treatment

10. Treated within 30 days of the Screening Visit with any antipsychotic medication

11. Treated within 30 days of the Screening Visit with any benzodiazepine or anticonvulsant medications

12. Current treatment with any restricted concomitant medication (i.e., NDRI, SSRI, SNRI, or QBDZ) that has not been stable for the preceding 60 days at the time of the Screening Visit

13. Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, stents, or electrodes) or any other metal object within the head, excluding the mouth, or on the head, that cannot be safely removed

14. Biomedical devices, including those not in or on the head, that are either implanted or not safe to remove, that may be affected by the magnetic field of the stimulator (e.g., cardiac pacemaker, cardioverter defibrillator (ICD), or medication dispensing device)

15. Clinically significant medical illness or condition, including, but not limited to, any uncontrolled thyroid disorders, hepatic, cardiac, pulmonary and renal malfunction, or chronic excessive alcohol consumption, that in the Investigator's judgment might pose a potential safety risk to the participant or limit the interpretation of trial results

16. Pregnant, or female unwilling to use effective birth control during the course of the trial

17. Plan to move away from the area, or knowledge that there will be an absence from the area, within 80 days following the Screening Visit (inclusive)

18. Unwilling or unable to adhere to the study treatment, data collection schedule, or study procedures, or any condition, including inability to communicate in English, which in the judgment of the Investigator might prevent the participant from completing the study, render study results uninterpretable, or represent an unacceptable safety risk to the participant or study personnel that is not otherwise listed in exclusion criteria.

19. Clinically significant psychopathology, including, but not limited to, schizophrenia or bipolar disorder, or other psychiatric disorder that in the Investigator's judgment might pose a potential safety risk to the participant, or limit the interpretation of trial results

20. An elevated risk of suicide or violence to others

21. Current psychotherapeutic treatment, expected to continue throughout the trial, that was begun in the preceding 60 days at the time of the Screening Visit

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change in PTSD Symptoms	Five weeks	Change in PTSD symptoms as measured by the PTSD Checklist-5 (PCL-5).

Trial Locations

Locations (8)

BrainHealth Solutions; 🇺🇸 Costa Mesa, California, United States

VA Long Beach Healthcare System; 🇺🇸 Long Beach, California, United States

SoCal Neuroscience Research Unit; 🇺🇸 San Diego, California, United States

UNC Rex Hospital; 🇺🇸 Raleigh, North Carolina, United States

Columbus Brain Research Center; 🇺🇸 Columbus, Ohio, United States

Center for Interventional Pain and Spine; 🇺🇸 Bryn Mawr, Pennsylvania, United States

Texas A&M Research Center; 🇺🇸 Plano, Texas, United States

Seattle Neuropsychiatric Treatment Center (Seattle NTC); 🇺🇸 Bellevue, Washington, United States